Cargando…
Sequencing the B Cell Receptor Repertoires of Antibody-Deficient Individuals With and Without Infection Susceptibility
PURPOSE: Most individuals with antibody deficiency (hypogammaglobulinemia) need immunoglobulin replacement therapy (IgG-RT) from healthy plasma donors to stay clear of infections. However, a small subset of hypogammaglobulinemic patients do not require this substitution therapy. We set out to invest...
Autores principales: | Lim, Yoong Wearn, Ramirez, Neftali Jose, Asensio, Michael A., Chiang, Yao, Müller, Gabriele, Mrovecova, Pavla, Mitsuiki, Noriko, Krausz, Máté, Camacho-Ordonez, Nadezhda, Warnatz, Klaus, Adler, Adam S., Grimbacher, Bodo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276080/ https://www.ncbi.nlm.nih.gov/pubmed/36826743 http://dx.doi.org/10.1007/s10875-023-01448-0 |
Ejemplares similares
-
Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018) -
Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4-Dependent Transendocytosis by Flow Cytometry
por: Rojas-Restrepo, Jessica, et al.
Publicado: (2023) -
Correction to: Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4‑Dependent Transendocytosis by Flow Cytometry
por: Rojas‑Restrepo, Jessica, et al.
Publicado: (2023) -
The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial
por: Krausz, Máté, et al.
Publicado: (2022) -
Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2022)